Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast Cancer
Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
Ecaterina Ileana Dumbrava, MD, an assistant professor in the Department of Investigational Cancer Therapeutics, of the Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
BDC-1001 is currently being studied in an ongoing phase 1 study to determine, safety, durability and proper dosage. According to Dumbrava, synergistic activity was seen between the 2 agents in preclinical models. These preclinical model also had anti-PB1 activity and immunologic memory.
It was hypothesized that the activity observed preclinically may translate in human subjects. Researchers hope that the combination will lead to a durable and sustained responses.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
FDA Grants Clearance for Phase 1 Trial of BL-M17D1 in Solid Tumors
November 11th 2024Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel antibody-drug conjugate BL-M17D1 in patients with advanced or metastatic solid tumors.
Read More
Study Reveals Encouraging Results in HER2+ Breast Cancer With Brain Mets
November 1st 2024Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Read More
